0000883975 2025-01-01 2025-03-31 0000883975 2025-05-12 0000883975 2025-03-31 0000883975 2024-12-31 0000883975 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember 2023-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000883975 us-gaap:RetainedEarningsMember 2023-12-31 0000883975 2023-12-31 0000883975 us-gaap:CommonStockMember 2024-12-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000883975 us-gaap:RetainedEarningsMember 2024-12-31 0000883975 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000883975 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000883975 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000883975 us-gaap:CommonStockMember 2024-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000883975 us-gaap:RetainedEarningsMember 2024-03-31 0000883975 2024-03-31 0000883975 us-gaap:CommonStockMember 2025-03-31 0000883975 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000883975 us-gaap:RetainedEarningsMember 2025-03-31 0000883975 MBOT:AtTheMarketOfferingProgramMember 2025-01-01 2025-03-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-03-31 0000883975 us-gaap:MoneyMarketFundsMember 2025-03-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2025-03-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0000883975 us-gaap:FairValueInputsLevel1Member 2025-03-31 0000883975 us-gaap:FairValueInputsLevel2Member 2025-03-31 0000883975 us-gaap:FairValueInputsLevel3Member 2025-03-31 0000883975 us-gaap:MoneyMarketFundsMember 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000883975 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000883975 MBOT:TwoThousandThirteenThroughMarchThirtyOneTwoThousandTwentyFiveMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-03-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2023-12-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2024-12-31 0000883975 MBOT:CardioSertLtdMember MBOT:IsraeliInnovationAuthorityMember 2022-10-06 2022-10-06 0000883975 srt:MinimumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-03-31 0000883975 srt:MaximumMember MBOT:IsraeliInnovationAuthorityMember 2025-01-01 2025-03-31 0000883975 MBOT:IsraeliInnovationAuthorityMember 2022-12-11 0000883975 MBOT:MinistryOfEconomyMember 2025-03-31 0000883975 srt:MinimumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 srt:MaximumMember MBOT:TechnionResearchAndDevelopmentFoundationLimitedMember 2012-06-01 2012-06-30 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2021-06-10 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-07-01 2024-07-01 0000883975 2022-10-03 2022-10-03 0000883975 MBOT:HCWainwrightAndCoLLCMember 2022-10-03 2022-10-03 0000883975 MBOT:AtTheMarketOfferingAgreementMember MBOT:HCWainwrightAndCoLLCMember 2022-10-06 2022-10-06 0000883975 MBOT:DeviceMember 2022-10-06 2022-10-06 0000883975 MBOT:IntegratedProductMember 2022-10-06 2022-10-06 0000883975 MBOT:SecuritiesPurchaseAgreementMember 2025-01-01 2025-03-31 0000883975 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2024-01-26 2024-01-26 0000883975 MBOT:LitigationSettlementMember 2023-12-31 0000883975 2023-01-01 2023-12-31 0000883975 MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 us-gaap:CommonStockMember MBOT:LitigationSettlementMember 2024-01-01 2024-03-31 0000883975 2025-03-01 2025-03-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2025-03-31 0000883975 MBOT:CertainEmployeesMember 2025-03-31 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SeriesGPreferredInvestmentOptionsMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-06 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SeriesHPreferredInvestmentOptionsMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-01-07 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SecuritiesPurchaseAgreementMember 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:SeriesIPreferredInvestmentOptionsMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:HCWainwrightAndCoLLCMember 2025-02-09 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2024-01-01 2024-12-31 0000883975 us-gaap:CommonStockMember MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:AtTheMarketOfferingAgreementMember 2025-01-01 2025-01-31 0000883975 MBOT:SeriesEPreferredInvestmentOptionsMember MBOT:ExerciseOfInvestmentOptionsMember 2025-01-01 2025-01-31 0000883975 us-gaap:PrivatePlacementMember 2025-01-01 2025-01-31 0000883975 srt:ChiefExecutiveOfficerMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 srt:ManagementMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndOtherExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-01-01 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-01-01 2024-12-31 0000883975 MBOT:ChiefExecutiveOfficerAndExecutivesMember 2024-12-31 0000883975 MBOT:CertainEmployeesMember 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-01-01 2024-12-31 0000883975 MBOT:AdvisorsMember 2024-12-31 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2024-02-29 0000883975 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-03-31 0000883975 MBOT:ExecutivesMember 2025-01-01 2025-03-31 0000883975 MBOT:CertainEmployeesAndCertainBoardMembersMember 2025-01-01 2025-03-31 0000883975 MBOT:BoardMember 2025-02-01 2025-02-28 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2025-03-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantSeriesEJanuaryTwoThousandTwentyFourMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2025-03-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantSeriesFJuneTwoThousandTwentyFourMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJuneTwoThousandTwentyFourMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantSeriesGJanuaryTwoThousandTwentyFiveMember 2025-03-31 0000883975 MBOT:WarrantSeriesGJanuaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesGJanuaryTwoThousandTwentyFiveMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandTwentyFiveMember 2025-03-31 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesHJanuaryTwoThousandTwentyFiveMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantSeriesIFebruaryTwoThousandTwentyFiveMember 2025-03-31 0000883975 MBOT:WarrantSeriesIFebruaryTwoThousandTwentyFiveMember 2024-12-31 0000883975 MBOT:WarrantSeriesIFebruaryTwoThousandTwentyFiveMember 2025-01-01 2025-03-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-03-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2024-12-31 0000883975 MBOT:WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember 2025-01-01 2025-03-31 0000883975 us-gaap:AllOtherSegmentsMember 2025-01-01 2025-03-31 0000883975 us-gaap:AllOtherSegmentsMember 2024-01-01 2024-03-31 0000883975 MBOT:SeriesEandSeriesFPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember 2025-04-01 2025-04-30 0000883975 MBOT:SeriesEandSeriesFPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember 2025-04-30 0000883975 us-gaap:SubsequentEventMember MBOT:HCWainwrightAndCoLLCMember 2025-04-01 2025-04-30 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember 2025-05-01 2025-05-31 0000883975 MBOT:SeriesFPreferredInvestmentOptionsMember us-gaap:SubsequentEventMember 2025-05-31 0000883975 us-gaap:SubsequentEventMember MBOT:HCWainwrightAndCoLLCMember 2025-05-01 2025-05-31 iso4217:USD shares iso4217:USD shares pure MBOT:Segment iso4217:ILS false --12-31 Q1 0000883975

10-Q true 2025-03-31 2025 false 000-19871 MICROBOT MEDICAL INC. DE 94-3078125 175 Derby St., Bld. 27 Hingham MA 02043 (781) 875-3605 Common Stock MBOT NASDAQ Yes Yes Non-accelerated Filer true false false 36377812 0.01

3217000

3114000

27173000

2356000

48000

49000

218000

300000

30656000

5819000

78000

80000

158000

132000

30892000

6031000

186000

165000

90000

70000

1617000

2225000

1893000

2460000

48000

41000

1941000

2501000

0.01

60000000

34744476

19399513

348000

195000

122148000

94279000

-93545000

-90944000

28951000

3530000

30892000

6031000

1459000

1169000

1562000

1215000

-3021000

-2384000

316000

104000

13000

-2601000

-2371000

-0.08

-0.17

31085606

14055973

11707317

118000

83884000

-79501000

4501000

1685682

17000

2380000

2397000

1005965 10000 1101000 1111000

529000

-2371000

14398964

145000

87894000

-81872000

6167000

19399513

195000

94279000

-90944000

3530000

19399513

195000

94279000

-90944000

3530000

13891840

139000

25778000

25917000

842606

8000

989000

997000

610517 6000 846000 852000

256000

-2601000

34744476

348000

122148000

-93545000

28951000

34744476

348000

122148000

-93545000

28951000

333000

2683000

10000

65000

64000

-2601000

-2371000

15000

28000

256000

453000

-73000

389000

-617000

-376000

-1335000 -1100000

-2874000

-2420000

13000

14000

28118000

5120000

3301000

1350000

2500000

-24830000

-1284000

27806000

2397000

27806000

2397000

102000

-1307000

3163000

2517000

3265000

1210000

47000

37000

30000 10000

1111000

76000

NOTE 1 – GENERAL A. Description of business Microbot Medical Inc. (the “Company”) is a pre-commercial, clinical-stage medical device company specializing in the research, design and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The Company is primarily focused on leveraging its micro-robotic technologies with the goal of redefining surgical robotics while improving surgical outcomes for patients. The Company incorporated on August 2, 1988 in the State of Delaware under the name Cellular Transplants, Inc. The original Certificate of Incorporation was restated on February 14, 1992 to change the name of the Company to Cyto Therapeutics, Inc. On May 24, 2000, the Certificate of Incorporation as restated was further amended to change the name of the Company to StemCells, Inc. On November 28, 2016, the Company consummated a transaction pursuant to an Agreement and Plan of Merger, dated August 15, 2016, with Microbot Medical Ltd., a private medical device company organized under the laws of the State of Israel (“Microbot Israel”). On the same day and in connection with the Merger, the Company changed its name from StemCells, Inc. to Microbot Medical Inc. On November 29, 2016, the Company’s common stock began trading on the Nasdaq Capital Market under the symbol “MBOT”. The Company and Microbot Israel, its sole subsidiary, are sometimes collectively referred to as the “Company” as the context may require. B. Risk Factors To date, the Company has not generated revenues from its operations. As of March 31, 2025, the Company had cash equivalents and marketable securities balance of approximately $30,390, excluding restricted cash. Due to continuing research and development and pre-commercialization activities, the Company expects to continue to incur additional losses for the foreseeable future. Notwithstanding these conditions, the Company’s management has concluded that the available funds as of the balance sheet date, combined with the capital raises completed as described in Note 6, are sufficient to fund the Company’s operations for more than twelve months from the issuance date of these financial statements. The Company expects to raise additional funds through future issuances of either debt and/or equity securities, including upon the cash exercise of outstanding investment options, and possibly additional grants from the Israeli Innovation Authority and other government institutions. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s stock, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Israel-Hamas War On October 7, 2023, the State of Israel, where our research and development and other operations are primarily based, suffered a surprise attack by hostile forces from Gaza, which led to Israeli military operation at first in Gaza and then in Lebanon. These military operations and related activities, such as the recent collapse of the Assad regime in Syria and Israel’s subsequent military operations in Syria, and the recent escalation of military operations by and against the Houthis in Yemen, are on-going as of the issuance date of these financial statements, although there have been temporary cease fires from time to time. The Company has considered various ongoing risks relating to the military operations and related matters, including: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">That some of our Israeli subcontractors, vendors, suppliers and other companies in which the Company relies, are currently only partially active, as instructed by the relevant authorities; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A slowdown in the number of international flights in and out of Israel.</td></tr></table> The Company is closely monitoring how the military operations and related activities could adversely affect our anticipated milestones and our Israel-based activities to support future clinical and regulatory milestones, including our ability to import materials that are required to construct the Company’s devices and to ship them outside of Israel. As of the issuance date of these financial statements, the Company has determined that there have not been any materially adverse effects on its business or operations, but the Company continues to monitor the situation, as any collapse of a cease-fire with Hamas or Hezbollah that may be in effect from time to time, or any further or future escalation or change could result in a material adverse effect on the ability of the Company’s Israeli office to support its clinical and regulatory activities. The Company does not have any specific contingency plans in the event of any such escalation or change. C. Unaudited Interim Financial Statements The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission (“SEC”) regulations. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). These interim consolidated condensed financial statements should be read in conjunction with the Company’s latest audited financial statements. Operating results for the three-month period ended March 31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025.

1988-08-02

30390000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the Company’s latest annual audited financial statements, except if noted below. Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates. Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zoqDybAioLsc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2025 and December 31, 2024: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250331_ztbuNiAxsh3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTXOwS3ULqse" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zU2hlgpsWCY6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zztgbj7iPgW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zzxoPFwHzL68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zgPC4xYE9vtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_zMGN38d7LlZ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zIxrwaSUCAP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTwGPLghlWme" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh851Lpvg328" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziryGrzLJfY8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zhykheiXoa76" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of March 31, 2025 and December 31, 2024. <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWeihp1WtSf2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company. <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrN3Sj1md5Zk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently adopted accounting pronouncements: In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. The ASU was effective for the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent interim periods. As part of the Annual Report for the year ended December 31, 2024, the Company adopted ASU 2023-07, which was applied retrospectively to all prior periods presented. Refer to Note 5 herein for further details regarding this adoption. <p id="xdx_844_ecustom--AccountingPronouncementsNotYetEffectivePolicyTextBlock_zXFre9HUmSNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt">Accounting pronouncements not yet effective: In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of operations. The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.

Basis of presentation: The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Use of estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions pertaining to transactions and matters whose ultimate effect on the financial statements cannot precisely be determined at the time of financial statements preparation. Although these estimates are based on management’s best judgment, actual results may differ from these estimates.

Fair value of financial instruments: The carrying values of cash and cash equivalents, other receivable and other accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of these instruments. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1 - Quoted prices (unadjusted) in active markets for identical assets and liabilities. Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. <p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zoqDybAioLsc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2025 and December 31, 2024: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250331_ztbuNiAxsh3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTXOwS3ULqse" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zU2hlgpsWCY6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zztgbj7iPgW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zzxoPFwHzL68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zgPC4xYE9vtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_zMGN38d7LlZ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zIxrwaSUCAP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTwGPLghlWme" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh851Lpvg328" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziryGrzLJfY8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zhykheiXoa76" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company’s financial assets are measured at fair value on a recurring basis by level within the fair value hierarchy. The Company’s money market funds are classified as Level 1. Other than that, the Company doesn’t have any other financial assets or financial liabilities marked to market at fair value as of March 31, 2025 and December 31, 2024.

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zoqDybAioLsc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">The following tables summarizes the Company’s financial assets subject to fair value measurement and the level of inputs used in such measurements as of March 31, 2025 and December 31, 2024: SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250331_ztbuNiAxsh3i" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTXOwS3ULqse" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zU2hlgpsWCY6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zztgbj7iPgW2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of March 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zzxoPFwHzL68" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zgPC4xYE9vtb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,173</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231_zMGN38d7LlZ2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zIxrwaSUCAP9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zTwGPLghlWme" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20241231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh851Lpvg328" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 44%">Marketable securities:</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 10%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_ziryGrzLJfY8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Money market mutual funds</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2,356</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AssetsFairValueDisclosure_iI_zhykheiXoa76" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Marketable securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,356</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

27173000

2356000

<p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWeihp1WtSf2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Share-based compensation: The Company applies ASC 718-10, “Share-Based Payment” (“ASC 718-10”), which requires the measurement and recognition of compensation expenses for all share-based payment awards made to employees and directors including stock options under the Company’s stock plans based on estimated fair values. ASC 718-10 requires companies to estimate the fair value of stock options using an option-pricing model, which is recognized as an expense over the requisite service periods in the Company’s statement of comprehensive loss, based on a straight-line method. The Company recognizes compensation cost for an equity classified award with only service conditions that has a graded vesting schedule on a straight-line basis over the requisite service period for the entire award, provided that the cumulative amount of compensation cost recognized at any date at least equals the portion of the grant date fair value of such award that is vested at that date. The Company recognizes the expense for an equity classified awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. If no explicit service period is determined, the Company estimates the implicit service period based on the timing the employee is expected to achieve the related performance condition. When no future services are required to be performed by the grantee in exchange for an award of equity instruments, and if such award does not contain a performance condition, the cost of the award is expensed on the grant date. The Company estimates the fair value of stock options granted as share-based payment awards using a Black-Scholes options pricing model. The option-pricing model requires a number of assumptions, of which the most significant are expected volatility and the expected option term (the time from the grant date until the options are exercised or expire). Expected volatility is estimated based on the standard deviation of the Company’s closing prices according to the expected life (SAB107) for each of the grants. The Company has historically not paid dividends and has no foreseeable plans to issue dividends. The risk-free interest rate is based on the yield from governmental zero-coupon bonds with an equivalent term. For stock options that qualify as “plain-vanilla,” the expected term is calculated using the simplified method. For stock options that do not qualify as “plain-vanilla”, the Company’s management estimated that the expected stock option term is the contractual term of the options. Changes in the determination of each of the inputs can affect the fair value of the stock options granted and the results of operations of the Company.

<p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zrN3Sj1md5Zk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Recently adopted accounting pronouncements: In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures” (“ASU 2023-07”) to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses on an interim and annual basis. All disclosure requirements of ASU 2023-07 are required also for entities with a single reportable segment. The ASU was effective for the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent interim periods. As part of the Annual Report for the year ended December 31, 2024, the Company adopted ASU 2023-07, which was applied retrospectively to all prior periods presented. Refer to Note 5 herein for further details regarding this adoption.

<p id="xdx_844_ecustom--AccountingPronouncementsNotYetEffectivePolicyTextBlock_zXFre9HUmSNh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.65pt; text-align: justify; text-indent: -49.65pt">Accounting pronouncements not yet effective: In November 2024, the FASB issued ASU 2024-03, “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220- 40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), which requires the disaggregation of certain expenses in the financial statements notes, to provide enhanced transparency into the expense captions presented on the face of the consolidated statement of operations. The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact that ASU 2024-03 will have on its related disclosures.

<p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zd86vzUVBUM9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">NOTE 3 - COMMITMENTS AND CONTINGENCIES A. Government grants: Microbot Israel has received grants from the IIA for participation in research and development since 2013 through March 31, 2025 totaling approximately $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20250101__20250331__us-gaap--AwardDateAxis__custom--TwoThousandThirteenThroughMarchThirtyOneTwoThousandTwentyFiveMember__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember_zdowwWuaZzJ6" title="Revenue grants received">1,878. This includes amounts received of approximately $378, in 2023 and 2024 which is a portion of an additional grant from the IIA in the amount of approximately NIS 1,620,000 (approximately $447) approved by the IIA on June 1, 2023, to further finance the development of the manufacturing process of the LIBERTY® Endovascular Robotic Surgical System. In addition, as a result of the agreement with Nitiloop, on October 6, 2022, Microbot Israel took over the liability to repay Nitiloop’s IIA grants in the aggregate amount of approximately $<span id="xdx_901_ecustom--RepaymentOfGovernmentGrants_pn3n3_c20221006__20221006__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__us-gaap--BusinessAcquisitionAxis__custom--CardioSertLtdMember_z9xL5cmG0cjc" title="Repayment of government grants">925. In relation to the IIA grants described above, the Company is obligated to pay royalties amounting to <span id="xdx_90F_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20250331__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MinimumMember_zxu5D4V1WlBe" title="Net sales royalty percenatge">3.0%-<span id="xdx_90A_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20250101__20250331__dei--LegalEntityAxis__custom--IsraeliInnovationAuthorityMember__srt--RangeAxis__srt--MaximumMember_zPJqq1wU7Mx5" title="Net sales royalty percenatge">5% of its future sales of the products relating to such grants. The grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bears interest of SOFR per year (SOFR is a benchmark interest rate which replaced LIBOR). The repayment of the grants is contingent upon the successful completion of the Company’s research and development programs and generating sales. The Company has no obligation to repay these grants, if the project fails, is unsuccessful or aborted or if no sales are generated. The financial risk is assumed completely by the Government of Israel. The grants are received from the Government on a project- by-project basis. On December 11, 2022, the Company received approval for a grant from the Ministry of Economy, in the amount of NIS 300,000 (approximately $83), for participation in expenses related to the LIBERTY® Endovascular Robotic Surgical System in the U.S. market. As of March 31, 2025, the Company received approximately $50 of such grant. In relation with the Ministry of Economy grant, the Company is obligated to pay royalties amounting to 3% of future sales of the LIBERTY® Endovascular Robotic Surgical System up to the grant amount plus interest. B. TRDF agreement: Microbot Israel signed an agreement with the Technion Research and Development Foundation (“TRDF”) in June 2012 by which TRDF transferred to Microbot Israel a global, exclusive, royalty-bearing license (as amended, the “License Agreement”) with respect to its then Self-Cleaning Shunt (SCS) project and TipCat assets, which also governed certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. As partial consideration for the license, Microbot Israel shall pay TRDF royalties on net sales (between <span id="xdx_906_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MinimumMember_zEMRDA2Xq2re" title="Net sales">1.5%-<span id="xdx_908_ecustom--NetSalesRoyaltyPercentage_pid_dp_uPure_c20120601__20120630__dei--LegalEntityAxis__custom--TechnionResearchAndDevelopmentFoundationLimitedMember__srt--RangeAxis__srt--MaximumMember_z9uruDZ4V5Lc" title="Net sales royalty percenatge">3.0%) and on sublicense income as detailed in the License Agreement. In October 2022 the Company suspended the SCS project and as a result of the Company’s May 2023 implementation of its core-business focus program and cost reduction plan, the Company returned the licensed intellectual property for the TipCat back to TRDF in June 2023 and returned the licensed intellectual property for the SCS (ViRob) back to TRDF in July 2023. As a result, as of the date of these financial statements, the License Agreement is limited to the certain technology relating to the Company’s LIBERTY® Endovascular Robotic Surgical System. C. ATM agreement: On June 10, 2021, the Company entered into an At-the-Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co. LLC (“Wainwright”), as sales agent, in connection with an “at the market offering” under which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock having an aggregate offering price of up to $<span id="xdx_90E_ecustom--OfferingCosts_iI_pn3n3_c20210610__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zlg3jlCs9Ezc" title="Offering costs">10,000 at market prices or as otherwise agreed with Wainwright. The Company entered into an amendment, dated July 1, 2024, to the ATM Agreement with Wainwright dated June 10, 2021, relating to the offer and sale of shares of the Company’s common stock having an aggregate offering price of up to approximately $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zFUmvm4Iy7Fb" title="Aggregate offering">4,820 from time to time through Wainwright, acting as sales agent. The compensation to Wainwright for sales of the shares is a placement fee of <span id="xdx_902_ecustom--PlacementFeePercent_pid_dp_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zhay9IyPtZx9" title="Percentage of placement fee">3.0% of the gross sales price of the shares of common stock sold pursuant to this ATM Agreement. See also Note 4B below. D. Engagement letters with H.C. Wainwright: In connection with registered direct and private placement offerings, the Company entered into engagement letters (the “Engagement Letters”) with Wainwright on October 3, 2022, on May 16, 2023, on October 24, 2023, and on May 29, 2024 which was amended most recently on February 9, 2025, in each case pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from offerings contemplated by the Engagement Letters, plus a management fee equal to 1.0% of the gross proceeds received by the Company from such offerings, as well as other reimbursable expenses. <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20221003__20221003__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zW5n2z7Fm3nk" title="Warrant issued, descriptions">The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. See also Note 4B below. E. Acquisition of Nitiloop’s assets: On October 6, 2022, Microbot Israel purchased substantially all of the assets, including intellectual property, devices, components and product related materials (the “Assets”), of Nitiloop Ltd., an Israeli limited liability company (“Nitiloop”). The Assets include intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter (the “Technology”) and the products or potential products incorporating the Technology owned by Nitiloop and designated by Nitiloop as “NovaCross”, “NovaCross Xtreme” and “NovaCross BTK” and any enhancements, modifications and improvements thereof (“Devices”). Microbot Israel did not assume any material liabilities of Nitiloop other than obligations Nitiloop has to the IIA and relating to certain renewal/maintenance fees for a European patent application. In consideration for the acquisition of the Assets, Microbot Israel shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20221006__20221006__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zu7zRS9yfxWe" title="Stock issued during period, value, new issues">8,000, as follows: Royalties at a rate of 3% of net revenue generated as a result of sales, license or other exploitation of the Devices; and Royalties at a rate of 1.5% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as part of an integrated product. F. Litigation resulting from the 2017 financing: The Company was named as the defendant in a lawsuit captioned Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient II, LP, Hudson Bay Master Fund Ltd., (the “Plaintiffs”), against Microbot Medical Inc., Defendant, in the Supreme Court of the State of New York, County of New York (Index No. 651182/2020) (the “Lawsuit”). The complaint alleged, among other things, that the Company breached multiple representations and warranties contained in the Securities Purchase Agreement (the “SPA”) related to the Company’s June 8, 2017 equity financing (the “2017 Financing”), of which the Plaintiffs participated, and fraudulently induced Plaintiffs into signing the SPA. The complaint sought rescission of the SPA and return of the Plaintiffs’ $<span id="xdx_909_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwO90zIMDoQa" title="Purchase price of plaintiffs">6,750 purchase price with respect to the 2017 Financing. On January 26, 2024 (the “Effective Date”), the Company entered into a settlement agreement and release with the Plaintiffs (the “Settlement Agreement”), effectively resolving the Lawsuit. Pursuant to the Settlement Agreement, the Company paid $2,154 consisting of a cash payment of $1,100, covered by the Company’s insurance company, and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240126__20240126__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember_znvZMRyMqsh9" title="Restricted common shares issued for legal settlement">1,005,965 shares of restricted common stock which were subsequently registered for resale. Furthermore, the Company’s insurance company is responsible for covering legal expenses incurred by the Company in relation to the legal proceedings of the Lawsuit. In February 2024, the Plaintiffs filed a stipulation discontinuing the Lawsuit with prejudice. The Company concluded the Settlement Agreement gave rise to loss contingencies in the scope of ASC Subtopic 450-20, Contingencies – Loss Contingencies, and as of December 31, 2023, the Company recorded a contingent liability, as the Company deemed it both probable and reasonably estimable. The Company determined that the loss contingency should be recognized as non-operating losses, offset by loss recoveries received from the Company’s insurance company. As a result of the Settlement Agreement and the insurance recovery received from the insurance company, as of December 31, 2023, the Company recorded a current liability and a current asset on its consolidated balance sheet totaling $2,211 and $1,335, respectively. Within this asset, $1,100 represents the recovery of the cash payment of the settlement amount, and $235 represents recovery of legal expenses. A net non-operating loss of $1,111 from legal settlement was reflected in the Company’s consolidated statement of comprehensive loss for the year ended December 31, 2023. In the first quarter of 2024, the Company received $1,335 from the insurance company. Additionally, during the first quarter of 2024, the Company paid the settlement amount by transferring $1,100 in cash to the Plaintiffs and issuing <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20240101__20240331__us-gaap--TypeOfArrangementAxis__custom--LitigationSettlementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zua0vCZT6Mhc" title="Number of share issued">1,005,965 shares of the Company’s common stock, thereby settling the liability recorded as of December 31, 2023. G. Mona litigation: In March 2025, an appellate court held in favor of the Company with respect to a 2019 action against Alliance Investment Management, Ltd., later amended to add Joseph Mona (“Mona”) as a defendant, in the Southern District of New York under Section 16(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), to compel Alliance and/or Mona to disgorge short swing profits realized from purchases and sales of the Company’s securities within a period of less than six months. As a result, the Company received a judgmet in the amount of approximately $316, net of legal fees and expenses. The amount received was recorded as other income in the Company’s condensed consolidated statement of comprehensive loss. Although the defendant has subsequently petitioned the United States Supreme Court for review to overturn the appellate court’s ruling, the Company believes the likelihood of the ruling being overturned to be remote. H. Accrued bonuses As of March 31, 2025, the Company recorded accrued bonuses to the CEO and other executives, in the aggregate amount of $176.

1878000

378000

1620000 1620000 447000 447000 925000 0.030 0.05

300000

83000

50000

0.03 0.015 0.030 10000000

4820000

0.030 0.070 0.010

The Company has also agreed to issue to Wainwright or its designees preferred investment options upon the closing of such offerings, equal to five (5.0%) percent of the aggregate number of such shares of common stock in such offerings, including upon exercise for cash of any warrants issued to investors in such offering. See also Note 4B below

8000000

0.03 0.015

6750000

2154000

1100000

1005965

2211000

1335000

1100000

235000

-1111000

1335000

1100000

1005965

316000

176000

<p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ztNlhtHESzE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">NOTE 4 - SHARE CAPITAL A. Registered direct and private placement offerings On January 6, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8fyEWHacQha" title="Shares issued">4,000,001 shares of the Company’s common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCLwOH9ZYYT2" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDvFbygb6Rz2">1.75 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250106__20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjNtMq1o24fi" title="Placement agent fee">7,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250106__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7iwm3HUzzdk" title="Offering expense">690. In a concurrent private placement, the Company agreed to issue to the investors series G preferred investment options to purchase up to <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember_zcPgkvRPVjPg" title="Shares issued">8,000,002 shares of common stock at an exercise price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesGPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKI1AkwslOx1" title="Exercise price">1.75 per share. Each Series G preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250106__20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zyjTP5EQvUy7" title="Options purchased">200,000 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250106__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zPeW0LO6e6Sj" title="Share price">2.1875 per share. On January 7, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfL3LtWXROR7" title="Shares issued">3,788,550 shares of the Company’s common stock, par value $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7vmvkQBp1Ab" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zunuukNrk1b">2.27 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250107__20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6q3mylZxiz5">8,600 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_904_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250107__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcFgeSwGGMLh" title="Offering expense">818. In a concurrent private placement, the Company agreed to issue to the investors series H preferred investment options to purchase up to <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember_zLufDeseT6Af" title="Shares issued">7,577,100 shares of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesHPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY2bMjQ1q7yh" title="Exercise price">2.10 per share. Each Series H preferred investment option is exercisable immediately and will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zvuRLgImkAwl" title="Options purchased">189,428 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zBX0Z2RcVrhd" title="Share price">2.8375 per share. On February 9, 2025, the Company entered into Securities Purchase Agreements with institutional investors, pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market, an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrjfLvZw7P78" title="Shares issued">6,103,289 shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zB15zWHymka3" title="Common stock, par value">0.01 per share, at an offering price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaIlyUxe0WG7">2.13 per share, for aggregate gross proceeds from the offerings of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20250209__20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyLiAboTdRw9">13,000 before deducting the placement agent fee and related offering expenses of approximately $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn3n3_c20250209__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDTvVo8hQet5" title="Offering expense">1,176. In a concurrent private placement, the Company agreed to issue to the investors series I preferred investment options to purchase up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember_zFB5aaSxfcef" title="Shares issued">12,206,578 shares of common stock at an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesIPreferredInvestmentOptionsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkNbR2Ax6Qui" title="Exercise price">2.13 per share. Each Series I preferred investment option is exercisable on the later of (i) the date on which the amendment to the Company’s articles of incorporation that increases the number of authorized shares of common stock to an amount of shares of common stock sufficient for the exercise in full of the series I preferred investment options is filed and accepted with the State of Delaware law (such date, the “Authorized Share Increase Date”) and (ii) the date on which approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any successor entity) from the stockholders of the Company with respect to the issuance of all the series I preferred investment options and the shares of common stock issuable upon the exercise thereof, is received and deemed effective under Delaware law (the “Initial exercise date”), and will expire two years from the initial exercise date. Net cash settlements are not permitted under any event under the Securities Purchase Agreements. The Company also issued to Wainwright or its designees preferred investment options to purchase up to <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250209__20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_z2vE6r0Yfe7b">305,164 shares of common stock which have the same terms as investors’ preferred investment options except for an exercise price equal to $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20250209__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember_zfiXo3r7y8Q" title="Share price">2.6625 per share. B. At-the-market offerings On July 1, 2024, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240701__20240701__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zWby1eobMtA8">4,820 of the Company’s shares of common stock pursuant to the ATM Agreement. During the year 2024, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zUaFBaE1hOId">3,433,880 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zYqJ8Dc0Rcv9" title="Total gross proceeds">3,756 before deducting sales agent commissions and other offering expenses of $239. In January 2025, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zmrSf9UCVlFd" title="Shares issued">842,606 shares of the Company’s common stock pursuant to the ATM Agreement, for total gross proceeds of approximately $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20250101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember_zVwym1FV87t4" title="Total gross proceeds">1,062 before deducting sales agent commissions and other offering expenses of $65. The Company is no longer selling its securities pursuant to the ATM Agreement and has not as of the filing of these financial statements entered into a new or replacement ATM agreement. C. Exercise of Investment Options In January 2025, the Company raised approximately $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pn3n3_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--ExerciseOfInvestmentOptionsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_zPBpfugUV6d9">916 in gross proceeds from the exercise of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20250101__20250131__us-gaap--TypeOfArrangementAxis__custom--ExerciseOfInvestmentOptionsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEPreferredInvestmentOptionsMember_z8UjcW2boHii">610,517 outstanding Series E preferred investment options, before deducting placement agent fee of $64. D. Equity classification The common stock of the Company are recognized as equity under the requirements of ASC Topic 505 Equity. The Company analyzed the accounting treatment for all of the outstanding preferred investment options. Based on the Company’s analysis all such warrants were classified as equity. The Company analyzed the accounting treatment for all of the outstanding preferred investment options issued to Wainwright. Since the Company did not identify any features causing liability classification according to ASC 718, it concluded that all such preferred investment options are equity-classified awards. E. Employee Stock Option Grants During the year ended December 31, 2024: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO, its executives and management, fully vested options to purchase an aggregate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOMot2NWx9V2" title="Agggregate number of options granted">80,000 and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zYdZeesSIsZj" title="Agggregate number of options granted">50,000 shares of the Company’s common stock, respectively, at an exercise price per share of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zMOVk9F0HzNl" title="Weighted-average exercise price per share, granted">1.2684.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO and certain executives, options to purchase an aggregate of <span id="xdx_90D_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQTnL1ZU9m1j" title="Additional number of stock options granted">80,000 and <span id="xdx_902_ecustom--AdditionalShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ManagementMember_zceKv4I1ejuk" title="Additional number of stock options granted">52,500 shares of the Company’s common stock, respectively, at an exercise price per share of $1.25. The vesting of these options is subject to the achievement of specified performance conditions. For the year ended December 31, 2024, the Company recorded an expense of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zYRrHMDjpgve" title="Compensation expenses">38, reflecting management’s assessment that the specified performance milestones for <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zp5hqE2MlTbk" title="Issued shares">35,625 of the <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndOtherExecutivesMember_zzWVAkVCgjv3" title="Agggregate number of options granted">132,500 options were achieved by their due date.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted the CEO, its executives, and certain employees, options to purchase an aggregate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerAndExecutivesMember_znCBlcCTo9Qj" title="Agggregate number of options granted">80,000 and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_zohxYm8AMajh" title="Agggregate number of options granted">115,000 shares of the Company’s common stock, respectively, at an exercise price per share of $1.2684, with a vesting period of three years.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company granted an advisor options to purchase an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__srt--TitleOfIndividualAxis__custom--AdvisorsMember_z1dTv0KIusYk" title="Agggregate number of options granted">25,000 shares of the Company’s common stock, at an exercise price per share of $0.881, with a vesting period of three years.</td></tr></table> With respect to the CEO’s 2023 annual bonus, during February 2024, the Company paid <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_dp_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zOXG0v5iSgV8" title="Compensation percentage">25% of the CEO’s total 2023 bonus – amounting to approximately $99, through the grant of fully vested options to purchase an aggregate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240201__20240229__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z92i7HwPpFwj" title="Agggregate number of options granted">79,567 shares of the Company’s common stock with an exercise price per share of $1.25. During the three months ended March 31, 2025, the Company granted the CEO, executives and certain employees, and certain board members, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zmhLOqybVBkb" title="Number of options granted">228,000, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__srt--TitleOfIndividualAxis__custom--ExecutivesMember_zsKiQopiUuS" title="Number of options granted">313,875 and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250331__srt--TitleOfIndividualAxis__custom--CertainEmployeesAndCertainBoardMembersMember_zDV8jRMyePzj" title="Number of options granted">70,000 options, respectively. In addition, in February 2025, the Company determined that <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zSNtSXKh1zgl" title="Number of options granted">35,625 out of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zAZMDDHlCZ65" title="Number of options vested">132,500 performance-based options granted in February 2024 had met their milestones and been vested, while the remainder <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250201__20250228__srt--TitleOfIndividualAxis__custom--BoardMember_zYdjgas9y6n3" title="Number of options forfeited">96,875 options which did not meet their milestones had been forfeited. F. Warrants: <p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmyvgTOnogy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">The remaining outstanding warrants and terms as of March 31, 2025 and December 31, 2024 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issuance date</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Outstanding and exercisable as of March 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercisable Through</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%">Warrant to underwriters October 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zLtrPLuFXFr8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%" title="Number of outstanding warrants"> 51,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zRMwGDIiGw05" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%" title="Number of outstanding warrants"> 51,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zS0Df6aqELA" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%" title="Exercise price">6.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zYcP1VjmgO8i" title="Exercisable Through">October 21, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters May 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zitOqiobu4K7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">32,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zmB2bKHXlGJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">32,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zn2v65Yslr0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zCfwKx43t7l" title="Exercisable Through">November 23, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters May 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zvHXxzfRx76b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">60,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_z87JMgxvvXH9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">60,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zWf27nFj2943" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zk9Ut5IV4Bj3" title="Exercisable Through">November 24, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zVB72LjrD283" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">35,088</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zcwB69MNv2Xl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">35,088</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_z0RuCCDB4sA1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_z6Upqshnmzme" title="Exercisable Through">June 2, 2028</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zP4kz8Jj0j1e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">31,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zDa4MWcKHRU5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">31,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zWIY2vl0Ccwi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zhyqm38zMJle" title="Exercisable Through">June 28, 2028</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series E January 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zAVeLm7ZAjGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">1,075,165</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zFGjRj8ME6uh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">1,685,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zpHD7untc2P5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zJJObgZUmFml" title="Exercisable Through">July 3, 2029</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zPkbJsXeFQhl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">84,284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zK3S2kxOT4Q4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">84,284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zC1Ny440anN3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.03</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_za7Nhab8Drmc" title="Exercisable Through">July 3, 2029</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series F June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zKlrZEyOTGil" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zEiZonejHb5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zxljxWr4aq6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zxVYKkMELSAa" title="Exercisable Through">June 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zlqWnoN3BOsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">78,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zeCGN0HrFt3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">78,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z01RK0jkhCP5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z5Wjy0vx2eV1" title="Exercisable Through">June 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series G January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zt2oJA9h0CQh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">8,000,002</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_z2EvHnlSekX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zvEpypgm9JXi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zmiTOOu8dDNd" title="Exercisable Through">January 7, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zpfCr2p8wJ35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zVDKRkxQnor3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zDlblK9tik8d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.1875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zUV7k8A33h9f" title="Exercisable Through">January 7, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series H January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zOVA6Vix9tXk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">7,577,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zw2nfHRgltZh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zCkz5DlJtTCk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zvC3z5u9GIl6" title="Exercisable Through">January 10, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z8pa8PfN3qt8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">189,428</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zqCGiHpPtzu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z1wc40HDrQed" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.8375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zGGknRPzZfB9" title="Exercisable Through">January 10, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zwdwcS5lxxN1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0" title="Number of outstanding warrants">30,526</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zA6l6PIsp709" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><p id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_z0jVeEvUP9Ci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0" title="Exercise price">1.875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_ztvzjnxgA3Dd" title="Exercisable Through">July 8, 2030</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series I February 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zm1VW6m2O1c9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">12,206,578</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zANI2jxPmKu9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zTzr6w2gJdih" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_fKCop_zfEGGxzO1fRf" title="Exercisable Through">(*)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters February 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zbmKjM7R4iA5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">305,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zTAyGeqgMMd4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zn9vriuVLSwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.6625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_fKCop_z3yqRn7iB9si" title="Exercisable Through">(*)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <td id="xdx_F09_zDCDKdjOots4" style="font: 10pt Times New Roman, Times, Serif; width: 5pt">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> See Note 4A.</td> </tr></table>

4000001

0.01

1.75

7000000

690000

8000002

1.75

200000

2.1875

3788550

0.01

2.27

8600000

818000

7577100

2.10

189428

2.8375

6103289

0.01

2.13

13000000

1176000

12206578

2.13

305164

2.6625

4820000

3433880

3756000

239000

842606

1062000

65000

916000

610517

64000

80000

50000

1.2684

80000 52500

1.25

38000

35625

132500

80000

115000

1.2684

25000

0.881

0.25

99000

79567

1.25

228000

313875

70000

35625

132500

96875

<p id="xdx_894_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zmyvgTOnogy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">The remaining outstanding warrants and terms as of March 31, 2025 and December 31, 2024 are as follows: SCHEDULE OF WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Issuance date</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Outstanding and exercisable as of March 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Outstanding and exercisable as of December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercisable Through</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%">Warrant to underwriters October 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zLtrPLuFXFr8" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%" title="Number of outstanding warrants"> 51,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zRMwGDIiGw05" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 11%" title="Number of outstanding warrants"> 51,125</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zS0Df6aqELA" style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%" title="Exercise price">6.11</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOctoberTwoThousandTwentyTwoMember_zYcP1VjmgO8i" title="Exercisable Through">October 21, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters May 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zitOqiobu4K7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">32,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zmB2bKHXlGJk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">32,778</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zn2v65Yslr0a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneMayTwoThousandTwentyThreeMember_zCfwKx43t7l" title="Exercisable Through">November 23, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters May 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zvHXxzfRx76b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">60,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_z87JMgxvvXH9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">60,476</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zWf27nFj2943" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoMayTwoThousandTwentyThreeMember_zk9Ut5IV4Bj3" title="Exercisable Through">November 24, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zVB72LjrD283" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">35,088</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_zcwB69MNv2Xl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">35,088</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_z0RuCCDB4sA1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.67</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersOneJuneTwoThousandTwentyThreeMember_z6Upqshnmzme" title="Exercisable Through">June 2, 2028</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2023</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zP4kz8Jj0j1e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">31,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zDa4MWcKHRU5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">31,231</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zWIY2vl0Ccwi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersTwoJuneTwoThousandTwentyThreeMember_zhyqm38zMJle" title="Exercisable Through">June 28, 2028</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series E January 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zAVeLm7ZAjGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">1,075,165</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zFGjRj8ME6uh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">1,685,682</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zpHD7untc2P5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesEJanuaryTwoThousandTwentyFourMember_zJJObgZUmFml" title="Exercisable Through">July 3, 2029</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zPkbJsXeFQhl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">84,284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zK3S2kxOT4Q4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">84,284</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_zC1Ny440anN3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.03</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFourMember_za7Nhab8Drmc" title="Exercisable Through">July 3, 2029</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series F June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zKlrZEyOTGil" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zEiZonejHb5f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">3,133,338</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zxljxWr4aq6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesFJuneTwoThousandTwentyFourMember_zxVYKkMELSAa" title="Exercisable Through">June 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters June 2024</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zlqWnoN3BOsg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">78,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_zeCGN0HrFt3g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">78,333</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z01RK0jkhCP5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.88</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJuneTwoThousandTwentyFourMember_z5Wjy0vx2eV1" title="Exercisable Through">June 3, 2026</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series G January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zt2oJA9h0CQh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">8,000,002</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_z2EvHnlSekX2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zvEpypgm9JXi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">1.75</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesGJanuaryTwoThousandTwentyFiveMember_zmiTOOu8dDNd" title="Exercisable Through">January 7, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zpfCr2p8wJ35" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">200,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zVDKRkxQnor3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zDlblK9tik8d" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.1875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveMember_zUV7k8A33h9f" title="Exercisable Through">January 7, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series H January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zOVA6Vix9tXk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">7,577,100</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zw2nfHRgltZh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zCkz5DlJtTCk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesHJanuaryTwoThousandTwentyFiveMember_zvC3z5u9GIl6" title="Exercisable Through">January 10, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z8pa8PfN3qt8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">189,428</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zqCGiHpPtzu" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_z1wc40HDrQed" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.8375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveOneMember_zGGknRPzZfB9" title="Exercisable Through">January 10, 2027</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters January 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants"><p id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zwdwcS5lxxN1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0" title="Number of outstanding warrants">30,526</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_zA6l6PIsp709" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"><p id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_z0jVeEvUP9Ci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0" title="Exercise price">1.875</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersJanuaryTwoThousandTwentyFiveTwoMember_ztvzjnxgA3Dd" title="Exercisable Through">July 8, 2030</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant series I February 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zm1VW6m2O1c9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">12,206,578</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zANI2jxPmKu9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_zTzr6w2gJdih" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.13</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantSeriesIFebruaryTwoThousandTwentyFiveMember_fKCop_zfEGGxzO1fRf" title="Exercisable Through">(*)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Warrant to underwriters February 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zbmKjM7R4iA5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">305,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zTAyGeqgMMd4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of outstanding warrants">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_zn9vriuVLSwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.6625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_ecustom--ClassOfWarrantOrRighstMonthYearFromWhichWarrantsOrRightsExercisable_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__custom--WarrantToUnderwritersFebruaryTwoThousandTwentyFiveTwoMember_fKCop_z3yqRn7iB9si" title="Exercisable Through">(*)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <td id="xdx_F09_zDCDKdjOots4" style="font: 10pt Times New Roman, Times, Serif; width: 5pt">(*)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> See Note 4A.</td> </tr></table>

51125

6.11

October 21, 2027

32778

2.75

November 23, 2026

60476

2.75

November 24, 2026

35088

2.67

June 2, 2028

31231

4.06

June 28, 2028

1075165

1685682

1.50

July 3, 2029

84284

2.03

July 3, 2029

3133338

1.50

June 3, 2026

78333

1.88

June 3, 2026

8000002

1.75

January 7, 2027

200000

2.1875

January 7, 2027

7577100

2.10

January 10, 2027

189428

2.8375

January 10, 2027

30526

1.875

July 8, 2030

12206578

2.13

(*)

305164

2.6625

(*)

NOTE 5 – SEGMENT REPORTING Segment information is prepared on the same basis that the Company’s chief operating decision maker (“CODM”), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment, which is the development of robotic devices for endoluminal surgery. See Note 1A for further details. The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents and marketable securities. The chief executive officer performs the assessment of segment performance by using the reported measure of segment loss to monitor actual results. <p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zargv7v6XIcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three months ended March 31, 2025 and 2024: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zcwcoNvjmSB3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_498_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zv61CEd0PC3f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left">Significant segment expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zmPywsfOfepj" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll and payroll related</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,067</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zXvwH7Wu5UZ3" style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Materials and subcontractors</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zuaYKVqRtWBh" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_zvX4IJ1cK7E2" style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other segment items (*)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">519</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">586</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zYs3cmrjqhZ5" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,601</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,371</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: left">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td></tr> </table>

<p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zargv7v6XIcl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify">The table below summarizes the significant expense categories regularly reviewed by the CODM for the three months ended March 31, 2025 and 2024: SCHEDULE OF STATEMENT OF OPERATION BY SEGMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_497_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zcwcoNvjmSB3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_498_20240101__20240331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--AllOtherSegmentsMember_zv61CEd0PC3f" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left">Significant segment expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--PayrollAndPayrollRelated_maNILzcOv_zmPywsfOfepj" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Payroll and payroll related</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,067</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MaterialsAndSubcontractors_maNILzcOv_zXvwH7Wu5UZ3" style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Materials and subcontractors</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_iN_di_msNILzcOv_zuaYKVqRtWBh" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Share-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">454</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--SegmentReportingOtherItemAmount_iN_di_msNILzcOv_zvX4IJ1cK7E2" style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other segment items (*)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">519</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">586</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzcOv_zYs3cmrjqhZ5" style="font: 10pt Times New Roman, Times, Serif; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,601</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,371</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 89%; margin-left: 0.75in"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; width: 20px; text-align: left">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.</td></tr> </table>

1548000 1067000 278000 264000

-256000

-454000

-519000

-586000

2601000

2371000

NOTE 6 – SUBSEQUENT EVENTS In April 2025, the Company raised approximately $<span id="xdx_901_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20250401__20250430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEandSeriesFPreferredInvestmentOptionsMember_zQBTNnHob234" title="Gross proceeds from option exercise">2,300 in gross proceeds from the exercise of an aggregate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesEandSeriesFPreferredInvestmentOptionsMember_zjnqaf3gCS43" title="Number of options outstanding">1,533,336 outstanding Series E and Series F preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company paid a cash fee of approximately $<span id="xdx_900_eus-gaap--PaymentsForFees_pn3n3_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxNZtdjCECH" title="Cash fee">161 to its placement agent and issued an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250401__20250430__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zVJGlzf11aY6" title="Options issued">76,667 placement agent options. In May 2025, the Company raised approximately $<span id="xdx_906_eus-gaap--ProceedsFromStockOptionsExercised_pn3n3_c20250501__20250531__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zeOlgyCgUvy4" title="Gross proceeds from option exercise">263 in gross proceeds from the exercise of an aggregate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20250531__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFPreferredInvestmentOptionsMember_zBgmTjm1k1hi" title="Number of options outstanding">175,000 outstanding Series F preferred investment options. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company will pay a cash fee of approximately $<span id="xdx_900_eus-gaap--PaymentsForFees_pn3n3_c20250501__20250531__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1a57Dnqydf9" title="Cash fee">18 to its placement agent and will issue an aggregate of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250501__20250531__us-gaap--TypeOfArrangementAxis__custom--HCWainwrightAndCoLLCMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmnYkYFSPMo2" title="Options issued">8,750 placement agent options.

2300000

1533336

161000

76667

263000

175000

18000

8750

false false false false Net of issuance costs in the amount of $333. See Note 3F. Net of issuance costs in the amount of $2,683, of which $10 had not been paid as of March 31, 2025. Net of issuance costs in the amount of $65. Net of issuance costs in the amount of $64. See Note 4A. Other segment items included within net loss include professional services, patents, overhead and depreciation, travel expenses, insurance expenses, financial income, net, other income and other miscellaneous expenses net of grants received. See the consolidated financial statements for other financial information regarding the Company’s operating segment.